首页> 外文期刊>Biopharmaceutics and Drug Disposition >Comparative pharmacokinetics of single doses of doxylamine succinate following intranasal, oral and intravenous administration in rats.
【24h】

Comparative pharmacokinetics of single doses of doxylamine succinate following intranasal, oral and intravenous administration in rats.

机译:大鼠鼻内,口服和静脉内给药后单剂量琥珀酸多西拉敏的比较药代动力学。

获取原文
获取原文并翻译 | 示例
           

摘要

The intranasal route of administration provides a potential useful way of administering a range of systemic drugs. In order to assess the feasibility of this approach for the treatment of nausea and vomiting, doxylamine succinate was studied in rats for the pharmacokinetics (AUC, C(max), t(max)) following intranasal, oral and intravenous administrations.Subjects (six male Sprague-Dawley rats per time interval for each route of administration) received 2-mg doses of doxylamine succinate orally and I-mg doses intranasally and intravenously, respectively. The various formulations were formulated in isotonic saline (0.9% w/v) at 25+/-1 degrees C. Doxylamine succinate concentrations in plasma were determined with a high-performance liquid chromatographic assay and a liquid-liquid extraction procedure. Intranasal and oral bioavailabilities were determined from AUC values relative to those after intravenous dosing.Intranasal bioavailability was greater than that of oral doxylamine succinate (70.8 vs 24.7%). The intranasal and oral routes of administration differed significantly from the intravenous route of administration. Peak plasma concentration (C(max)) was 887.6 ng/ml (S.D. 74.4), 281.4 ng/ml (S.D. 24.6) and 1296.4 ng/ml (S.D. 388.9) for the intranasal, oral and intravenous routes, respectively. The time to achieve C(max) for the intranasal route (t(max)=0.5 h) was faster than for the oral route (t(max)=1.5 h), but no statistically significant differences between the C(max) values were found using 95% confidence intervals. The results of this study show that doxylamine succinate is rapidly and effectively absorbed from the nasal mucosa.
机译:鼻内给药途径提供了潜在的有用的方式来给药一系列全身药物。为了评估这种方法治疗恶心和呕吐的可行性,研究了大鼠鼻内,口服和静脉内给药后琥珀酸多西拉敏琥珀酸盐的药代动力学(AUC,C(max),t(max))。对于每种给药途径,每个时间间隔的雄性Sprague-Dawley大鼠)分别口服2mg剂量的琥珀酸多西拉敏和鼻内和静脉内给药1mg。将各种制剂在等渗盐水(0.9%w / v)中于25 +/- 1摄氏度下配制。采用高效液相色谱测定法和液-液萃取程序测定血浆中的丁二胺琥珀酸酯浓度。相对于静脉内给药后的AUC值确定鼻内和口服的生物利用度。鼻内生物利用度大于琥珀酸多西拉敏(70.8 vs 24.7%)。鼻内和口服给药途径与静脉内给药途径明显不同。鼻内,口服和静脉内途径的血浆峰值浓度(C(max))分别为887.6 ng / ml(S.D. 74.4),281.4 ng / ml(S.D. 24.6)和1296.4 ng / ml(S.D. 388.9)。鼻内途径(t(max)= 0.5 h)达到C(max)的时间比口服途径(t(max)= 1.5 h)快,但C(max)值之间无统计学差异使用95%置信区间发现。这项研究的结果表明,琥珀酸多西拉敏被鼻粘膜迅速有效地吸收。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号